



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
P.O. Box 1450  
ALEXANDRIA, VA 22313-1450  
www.uspto.gov

Michael J. Jaro, Esq.  
Chief Patent Counsel  
Medtronic Vascular  
3576 Unocol Place  
Santa Rosa CA 95403

MAILED #18  
JAN 05 2004

REEXAM UNIT

In re Application for Patent Term Extension for:  
U.S. Patent No. 5,836,965  
Filed: November 26, 2003

A review of the Office assignment records do not reflect that the change of name from Medtronic AVE to Medtronic Vascular was recorded. Exhibit A otherwise appears to include records of the chain of title from the inventor to Medtronic AVE, but does not appear to include a document demonstrating the change of name.

Applicant is required to record the change of name from Medtronic AVE to Medtronic Vascular. If the above-identified patent is extended under 35 U.S.C. 156, the extension will issue to the assignee of record at the time of mailing of the Notice of Final Determination, e.g., Medtronic AVE, Inc.

Inquiries regarding this communication should be directed to the undersigned at (703) 306-3159 (telephone) or (703)872-9411 (facsimile).



Karin Ferriter  
Senior Legal Advisor  
Office of Patent Legal Administration  
Office of the Deputy Commissioner  
for Patent Examination Policy



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
P.O. Box 1450  
ALEXANDRIA, VA 22313-1450  
www.uspto.gov

#17

David T. Read  
Acting Director Health Assessment Policy Staff, CDER  
Food and Drug Administration  
1451 Rockville Pike, HFD-7  
Rockville, MD 20852

**MAILED**

**JAN 05 2004**

**REEXAM UNIT**

Dear Mr. Read:

The attached application for patent term extension of U.S. Patent No. 5,836,965 was filed on November 26, 2003, under 35 U.S.C. § 156.

The assistance of your Office is requested in confirming that the product identified in the application, S8 Over-the-Wire System (Driver® Stent Delivery System), has been subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g) before its first commercial marketing or use and that the application for patent term extension was filed within the sixty-day period after the product was approved. Since a determination has not been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, or a method of manufacturing or use of such a product, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156. It is noted that applications for patent term extension for U.S. Patent Nos. 5,292,331, 5,800,509, 5,836,965, 5,879,382, 5,891,190, 6,159,229, 6,309,402 and 6,344,053 were filed based upon the regulatory review period of the same medical device, and that a single patent would be required to be elected for extension.

Inquiries regarding this communication should be directed to the undersigned at (703) 306-3159 (telephone) or (703)872-9411 (facsimile).



Karin Ferriter  
Senior Legal Advisor  
Office of Patent Legal Administration  
Office of the Deputy Commissioner  
for Patent Examination Policy

cc: Michael J. Jaro, Esq.  
Chief Patent Counsel  
Medtronic Vascular  
3576 Unocol Place  
Santa Rosa CA 95403